Related Experiment Video

Updated: Dec 28, 2025

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.0K

Current State of Systemic Therapies for Advanced Renal Cell Carcinoma

Shuchi Gulati1, Ulka Vaishampayan2

  • 1University of Cincinnati, Cincinnati, OH, USA.

Current Oncology Reports
|February 13, 2020
PubMed
Abstract

Insights

New systemic therapies, including immune checkpoint inhibitors, are transforming kidney cancer treatment. This review covers current regimens, sequencing, and future directions for managing renal cell carcinoma.

Area of Science:

  • Oncology
  • Nephrology
  • Immunotherapy

Background:

  • The landscape of kidney cancer therapeutics is rapidly evolving.
  • Metastatic renal cell carcinoma (RCC) management has been revolutionized by novel systemic therapies.

Purpose of the Study:

  • To review the current state of systemic therapy for kidney cancer.
  • To discuss the sequencing of treatments, including cytoreductive nephrectomy.
  • To explore the role of biomarkers and novel therapeutic targets in RCC management.

Main Methods:

  • Literature review of recent advancements in kidney cancer therapeutics.
  • Analysis of clinical trial data and treatment guidelines.
  • Discussion of emerging biomarkers and therapeutic targets.

Main Results:

  • Immune checkpoint inhibitors (ICIs), such as programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors, are now frontline treatments for metastatic RCC.
  • Combinations of ICIs with cytotoxic T lymphocyte-associated protein-4 (CTLA-4) inhibitors and tyrosine kinase inhibitors (TKIs) have shown improved outcomes.
  • Significant progress has been made in refining existing targets and identifying new ones.

Conclusions:

  • Optimal sequencing of therapies and management of treatment resistance remain critical challenges.
  • Biomarkers are essential for personalizing treatment, minimizing costs, and improving outcomes in kidney cancer.
  • Continued research is needed to address unmet needs in advanced renal cell carcinoma treatment.
Keywords:
Clear cellKidney cancerNephrectomyNon-clear cellTreatment

More Related Videos

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

34.0K
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
281
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K